Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Oral Compositions of Ketamine and Related Compounds

SOUTHBOROUGH, Mass., Jan. 9, 2018 /PRNewswire/ -- Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, announced today that its patent application for oral compositions of ketamine and related compounds was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The U.S. patent will not expire until after 2033. 

"This new patent directed toward Amorsa's anticipated commercial formulations marks another significant accomplishment for the company," said Dr. Alex Nivorozhkin, COO of Amorsa and co-inventor on this patent.  "There's tremendous commercial potential for Amorsa's technology to treat several nervous system disorders including treatment-resistant depression, moderate-to-severe pain, PTSD, Rett syndrome and other related conditions. The patent broadens Amorsa's wholly owned intellectual property portfolio, especially as it relates to ketamine and ketamine-related compounds."

About Amorsa Therapeutics
Amorsa is a neuropharmaceutical company pioneering the development and commercialization of breakthrough treatments for nervous system disorders including moderate-to-severe pain and treatment-resistant depression. Founded in 2013, Amorsa has assembled a leadership team with experience in building several successful life science companies and has a strong track record in developing novel therapeutic treatments.  In addition, Amorsa has attracted leading neuroscience and pain management experts to join its Scientific and Clinical Advisory Board. For more information, visit www.amorsatx.com. 

SOURCE Amorsa Therapeutics, Inc.